What To Do About Caronia
This article was originally published in RPM Report
Executive Summary
While pharmaceutical marketers wait to hear how the government will respond to the Second Circuit’s off-label communication Caronia court ruling, PhRMA is considering ways to take the initiative. On the table: working proactively with FDA to re-frame the rules around off-label promotion.
You may also be interested in...
Off-label Ruling’s Potential Fallout Is “Terrifying,” FDA’s Temple Says
If firms could promote drugs for uses not backed by well-controlled studies, it would be “a nightmare,” Temple says; AEI’s Scott Gottlieb suggests the agency might try to regulate how medicines are prescribed.
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling
In a watershed decision, a federal appeals court declares that manufacturers cannot be prosecuted under the FD&C Act’s misbranding provisions solely for speech promoting off-label use of a drug. Industry attorneys predict the decision, if it stands, will change the government’s approach to pursuing such cases.
US FDA’s Inner Circle Takes Shape: Shah Seen As Potential Successor To Abernethy
Anand Shah returns to FDA as deputy commissioner; like Abernethy, he is an oncologist with a background in big data.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: